Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Diabetes Management Firms Shun VA Medical Product Standardization

This article was originally published in The Gray Sheet

Executive Summary

Diabetes testing equipment manufacturers are uniting to dissuade the Department of Veterans Affairs from issuing a request for proposals (RFP) that would standardize clinical preference products nationwide

You may also be interested in...



DME competitive bidding

Diabetes product manufacturers favor administrative route over legislation to convince CMS that glucose monitors are sufficiently distinct from other durable medical equipment, prosthetics, orthotics and supplies to be omitted from products eligible for competitive bidding when the agency releases a notice of proposed rulemaking this summer. CMS' Program Oversight & Advisory Committee meets in Baltimore Feb. 28-March 2 to mull recommendations for implementing the program. Diabetes management firms also will work with Secretary of Veterans Affairs Jim Nicholson, sworn in Feb. 1, against procurement standardization of the products (1"The Gray Sheet" July 5, 2004, p. 3)...

Chinese Firms Up Their Game In Novel Flu Antiviral Development

Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT020501

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel